Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Biopharma company presents study results for anticancer agent at conference
December 28th, 2004
Novacea Inc. announced that it presented preclinical study results of its anticancer agent, AQ4N (banoxantrone), at the Annual American Society for Hematology (ASH) meeting in San Diego, California. The data indicate that AQ4N has activity against lymphoma and leukemia cell lines and the ability to target lymphatic tissues with minimal systemic toxicity. "We are encouraged by these findings that suggest the potential benefit of AQ4N in the treatment of lymphoproliferative diseases, in addition to the benefit previously seen in solid tumors," said John Curd, MD, Novacea's chief medical officer. Curd continued, "Many treatments for...
Source: Cancer Weekly (2004-12-28)
|
